Exagen (XGN) Invested Capital (2018 - 2026)

Exagen (XGN) has reported Invested Capital for 9 consecutive years, with $37.3 million the latest figure, recorded in Q1 2026.

• Invested Capital for Q1 2026 came in at $37.3 million, up 42.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.3 million (up 42.36% YoY), and the FY2025 annual result was $39.1 million, up 36.69% from the prior year.
• Invested Capital was $37.3 million for Q1 2026 at Exagen, down from $39.1 million in the prior quarter.
• Over five years, Invested Capital peaked at $103.8 million in Q1 2022 and troughed at $26.2 million in Q1 2025.
• Average Invested Capital over 5 years is $51.8 million, with a median of $41.4 million recorded in 2023.
• Year-over-year, Invested Capital sank 44.23% in 2023 and jumped 42.36% in 2026.
• Over 5 years, Invested Capital stood at $70.8 million in 2022, then sank by 41.5% to $41.4 million in 2023, then plunged by 30.81% to $28.6 million in 2024, then jumped by 36.69% to $39.1 million in 2025, then declined by 4.72% to $37.3 million in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were $37.3 million in Q1 2026, $39.1 million in Q4 2025, and $41.1 million in Q3 2025.